Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-101 in refractory lupus nephritis and systemic lupus erythematosus
NCT06265220Phase 1Active, not recruiting
- Sponsor
- Artiva Biotherapeutics, Inc.
- Start
- Apr 2024
- Primary completion
- Aug 2027
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of AlloNK in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (3 arms), sponsored by Artiva Biotherapeutics, Inc. Primary endpoints: Treatment-Emergent Adverse Events at 104 weeks, Serious Adverse Events at 104 weeks and 1 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
AlloNK
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06265220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06265220.